SerpinE2 promotes multiple cell proliferation and drug resistance in osteosarcoma

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Serpins E2 (SerpinE2) are known to inhibit serine proteases and are implicated in tumor progression and metastasis.
• The specific role of SerpinE2 in osteosarcoma progression remains largely undetermined.

Purpose of the Study:

• To investigate the expression and function of SerpinE2 in osteosarcoma.
• To determine the correlation between SerpinE2 expression and clinical outcomes, including metastasis, chemotherapy response, and patient survival.

Main Methods:

• Analysis of SerpinE2 expression in osteosarcoma tissues across different stages.
• In vitro studies involving SerpinE2 overexpression in osteosarcoma cell lines (MG-63, SAOS-2).
• Assessment of cell proliferation, colony formation, drug resistance (bortezomib, doxorubicin), and cell cycle-related gene expression (CDK4, cyclin D1).

Main Results:

• SerpinE2 expression is significantly higher in osteosarcoma tissues, particularly in metastatic and advanced stage (II-III) tumors.
• Post-chemotherapy SerpinE2 levels were elevated compared to diagnosis.
• SerpinE2 overexpression increased cell proliferation, colony formation, and resistance to bortezomib and doxorubicin.
• Positive correlation observed between SerpinE2 expression and cell cycle regulators CDK4 and cyclin D1.
• High SerpinE2 expression is linked to poorer patient survival rates.

Conclusions:

• Elevated SerpinE2 expression in osteosarcoma drives tumor progression by stimulating proliferation and enhancing drug resistance.
• SerpinE2 regulates CDK4 and cyclin D1, contributing to poor survival outcomes.
• SerpinE2 represents a potential therapeutic target for osteosarcoma treatment.